The peculiar and nonunivocal link between anti-TNF alpha agents and ILD is clearly represented by a patient described by Komiya et al.; in this case report the administration of adalimumab first improved preexisting RA-ILD, and then induced its progression [104]. The gene discussed is TNF; the disease is interstitial lung disease.